LONDON (Reuters) - Pfizer's new chronic myeloid leukaemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said on Tuesday.
The latest draft guidance from the National Institute for Health and Clinical Excellence (NICE), which is subject consultation, follows two earlier rebuffs for new cancer drugs developed by Pfizer this year.
(Reporting by Ben Hirschler; Editing by David Cowell)
Source: http://news.yahoo.com/pfizer-gets-fresh-cancer-drug-rejection-nice-231139835.html
chick fil a Emmett Till Janet Napolitano John Deere Classic Boston Strangler black Ed Sheeran
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.